Use of triclosan-eluting ureteral stents in patients with long-term stents

Journal of Endourology

Volumn 23, Issue 7, 2009, Pages 1187-1194

  Cadieux, Peter A ^a,b   Chew, Ben H ^c   Nott, Linda ^a,b   Seney, Shannon ^a   Elwood, Chelsea N ^a   Wignall, Geoffrey R ^b   Goneau, Lee W ^a   Denstedt, John D ^a,b,d  

^a LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFAZOLIN; LEVOFLOXACIN; TRICLOSAN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; BIOFILM; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE INFECTION; DRUG ELUTING STENT; ENTEROCOCCUS; HUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; URETER STENT; URINARY TRACT INFECTION; URINE CULTURE;

ANTI-INFECTIVE AGENTS, LOCAL; BACTERIA; BIOFILMS; CATHETER-RELATED INFECTIONS; CATHETERS, INDWELLING; DRUG RESISTANCE, BACTERIAL; DRUG-ELUTING STENTS; HUMANS; MICROSCOPY, ELECTRON, SCANNING; TIME FACTORS; TRICLOSAN; URETER; URINE;

EID: 67650783485     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2008.0437     Document Type: Article

References (21)

1. Denstedt JD, Wollin TA, Reid G. Biomaterials used in urology: Current issues of biocompatibility, infection, and encrustation. J Endourol 1998;12:493-500. (Pubitemid 29043782)
2. Choong S, Whitfield H. Biofilms and their role in infections in urology. BJU Int 2000;86:935-941. (Pubitemid 30842206)
3. Schierholz JM, Beuth J. Implant infections: A haven for opportunistic bacteria. J Hosp Infect 2001;49:87-93. (Pubitemid 32982681)
4. Peters HJ. [Antibiotic treatment of complicated urinary tract infections.] Z Arztl Fortbild ( Jena) (Ger) 1995;89:279-286.
5. Barbolt TA. Chemistry and safety of triclosan, and its use as an antimicrobial coating on Coated VICRYL* Plus Antibacterial Suture (coated polyglactin 910 suture with triclosan). Surg Infect 2002;3(suppl 1):S45-S53.
6. Eifler-Bollen R, Fluhr JW. [Antimicrobially effective compounded medications. Clinical value and critical comments]. (Ger) Hautzarzt 2005;56:752-758.
7. Kramer A, Guggenbichler P, Heldt P, Jünger M, Ladwig A, thierbach H, Wever U, Daeschlein G. Hygienic relevance and risk assessment of antimicrobial-impregnated textiles. Curr Probl Dermatol 2006;33:78-109.
8. Heath RJ, White SW, Rock CO. Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. Appl Microbiol Biotechnol 2002;58:695-703. (Pubitemid 34493930)
9. Zhang YM, Lu YJ, Rock CO. The reductase steps of the type II fatty acid synthase as antimicrobial targets. Lipids 2004;39:1055-1060.
10. Gilbert P, McBain AJ. Literature-based evaluation of the potential risks associated with impregnation of medical devices and implants with triclosan. Surg Infect (Larchmt) 2002;3(suppl 1):S55-S63. (Pubitemid 36163627)
11. Gaffar A, Scherl D, Afflitto J, Coleman EJ. The effect of triclosan on mediators of gingival inflammation. J Clin Periodontol 1995;22:480-484.
12. Kjaerheim V, Barkvoll P, Waaler SM, Rölla G. Triclosan inhibits histamine-induced inflammation in human skin. J Clin Periodontol 1995;22:423-426.
13. Xu T, Deshmukh M, Barnes VM, Trivedi HM, Cummins D. Effectiveness of a triclosan/copolymer dentifrice on microbiological and inflammatory parameters. Compend Contin Educ Dent 2004;25(suppl 1):46-53.
14. Williams GJ, Stickler DJ. Some observations on the diffusion of antimicrobial agents through the retention balloons of foley catheters. J Urol 2007;178:697-701.
15. Cadieux PA, Chew BH, Knudsen BE, Dejong K, Rowe E, Reid G, Denstedt JD. Triclosan loaded ureteral stents decrease proteus mirabilis 296 infection in a rabbit urinary tract infection model. J Urol 2006;175:2331-2335. (Pubitemid 43668543)
16. Chew BH, Cadieux PA, Reid G, Denstedt JD. In-vitro activity of triclosan-eluting ureteral stents against common bacterial uropathogens. J Endourol 2006;20:949-958. (Pubitemid 44907031)
17. Chuanchuen R, Karkhoff-Schweizer RR, Schweizer HP. Highlevel triclosan resistance in Pseudomonas aeruginosa is solely a result of efflux. Am J Infect Control 2003;31:124-127. (Pubitemid 36432870)
18. Perwaiz S, Barakzi Q, Farooqi BJ, Khursheed N, Sabir N. Antimicrobial susceptibility pattern of clinical isolates of methicillin resistant Staphylococcus aureus. J Pak Med Assoc 2007;57:2-4. (Pubitemid 47202810)
19. Beiko DT, Watterson JD, Knudsen BE, Nott L, Pautier SE, Brock GB, Razvi H, Denstedt JD. Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. J Endourol 2004;18:723-730. (Pubitemid 39441760)
20. Riedl CR, Plas E, Hübner WA, Zimmerl H, Ulrich W, Pflüger H. Bacterial colonization of ureteral stents. Eur Urol 1999;36:53-59.
21. Seefeld MA, Miller WH, Newlander KA, et al. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J Med Chem 2003;46:1627-1635.